Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
GRCE
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (GRCE) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C
Value
C+
Factor Score
2.5
/ 5.0
Growth
C-
Factor Score
2.1
/ 5.0
Profitability
C+
Factor Score
2.7
/ 5.0
Momentum
C+
Factor Score
2.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-4.1
EV / EBITDA
-2.4
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-10.1%
Price Return 12M
-37.8%
Catalyst Signal
0.00
Market Cap
$39.0M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-36.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C- (2.1) | C+ (2.7) | C+ (2.5) | C+ (2.6) | C (2.5) |
| 2026-11-05 | C+ (2.5) | C- (2.1) | C+ (2.7) | C (2.4) | C+ (2.7) | C (2.5) |
| 2026-10-29 | C+ (2.5) | C- (2.0) | C+ (2.7) | C+ (2.6) | C+ (2.7) | C+ (2.5) |
| 2026-10-22 | C+ (2.5) | C- (2.0) | C+ (2.7) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-10-15 | C+ (2.5) | C- (2.0) | C+ (2.7) | D+ (1.7) | C+ (2.6) | C (2.3) |
Page
1
of
4